Boston Scientific Corporation (BSX) continues to gain the attention of analysts and investors. The company has positive ratings from brokerage firms such as Needham, which reiterated its 'buy' rating based on its IVL market opportunities.
Several other institutional investors, likewise, are showing trust in the company by expanding their stakes, such as Exchange Traded Concepts, IFM Investors, and Assenagon Asset Management. The company did, however, also see some investors trimming their positions, including Gradient Investments and Sapient Capital. Even amidst some market fluctuations,
BSX stock continues its impressive performance. It even lifted its long-term growth outlook ahead of its Investor Day, reflecting confidence in its future prospects. Expanding on specific entities, Oppenheimer applauded the company, describing it as the best large-cap MedTech. In the second quarter of 2025, the company achieved good results and affirmed a buy rating. The company was in news for a
positive forecast for its Q1 earnings as well and even managed to outperform S&P 500. BSX's financial performance has drawn a bullish sentiment. The
BSX shares have seen a substantial increase by firms and its
valuation is considered worth the price despite being expensive. Thanks to its strong Q2 results, Oppenheimer uplifts BSX price target to $118. The highlight of their business activities involves acquiring BioEnvelope business from Elutia for $88 Million, further asserting its position in the medical market's growth trajectory.
Boston Scientific Corp BSX News Analytics from Wed, 26 Feb 2025 08:00:00 GMT to Sat, 20 Sep 2025 21:55:31 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -4
